Literature DB >> 35263761

Phosphoantigen-Stimulated γδ T Cells Suppress Natural Killer-Cell Responses to Missing-Self.

Katherine Walwyn-Brown1,2, Jason Pugh1,2, Alexander T H Cocker1,2, Niassan Beyzaie1,2, Bernhard B Singer3, Daniel Olive4, Lisbeth A Guethlein1,2, Peter Parham1,2, Zakia Djaoud1,2.   

Abstract

γδ T cells stimulated by phosphoantigens (pAg) are potent effectors that secrete Th1 cytokines and kill tumor cells. Consequently, they are considered candidates for use in cancer immunotherapy. However, they have proven only moderately effective in several clinical trials. We studied the consequences of pAg-stimulated γδ T-cell interactions with natural killer (NK) cells and CD8+ T cells, major innate and adaptive effectors, respectively. We found that pAg-stimulated γδ T cells suppressed NK-cell responses to "missing-self" but had no effect on antigen-specific CD8+ T-cell responses. Extensive analysis of the secreted cytokines showed that pAg-stimulated γδ T cells had a proinflammatory profile. CMV-pp65-specific CD8+ T cells primed with pAg-stimulated γδ T cells showed little effect on responses to pp65-loaded target cells. By contrast, NK cells primed similarly with γδ T cells had impaired capacity to degranulate and produce IFNγ in response to HLA class I-deficient targets. This effect depended on BTN3A1 and required direct contact between NK cells and γδ T cells. γδ T-cell priming of NK cells also led to a downregulation of NKG2D and NKp44 on NK cells. Every NK-cell subset was affected by γδ T cell-mediated immunosuppression, but the strongest effect was on KIR+NKG2A- NK cells. We therefore report a previously unknown function for γδ T cells, as brakes of NK-cell responses to "missing-self." This provides a new perspective for optimizing the use of γδ T cells in cancer immunotherapy and for assessing their role in immune responses to pAg-producing pathogens. See related Spotlight by Kabelitz, p. 543. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35263761      PMCID: PMC9064994          DOI: 10.1158/2326-6066.CIR-21-0696

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   12.020


  52 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

Review 2.  Cytotoxic immunological synapses.

Authors:  Michael L Dustin; Eric O Long
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Harnessing γδ T cells in anticancer immunotherapy.

Authors:  Dalil Hannani; Yuting Ma; Takahiro Yamazaki; Julie Déchanet-Merville; Guido Kroemer; Laurence Zitvogel
Journal:  Trends Immunol       Date:  2012-02-23       Impact factor: 16.687

4.  Functionally distinct subsets of human gamma/delta T cells.

Authors:  C T Morita; S Verma; P Aparicio; C Martinez; H Spits; M B Brenner
Journal:  Eur J Immunol       Date:  1991-12       Impact factor: 5.532

5.  Reduced NK activity in pulmonary tuberculosis patients with/without HIV infection: identifying the defective stage and studying the effect of interleukins on NK activity.

Authors:  R Nirmala; P R Narayanan; R Mathew; M Maran; C N Deivanayagam
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

6.  Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells.

Authors:  E Sturm; E Braakman; P Fisch; R J Vreugdenhil; P Sondel; R L Bolhuis
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

7.  LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII.

Authors:  Takumi Maruhashi; Il-Mi Okazaki; Daisuke Sugiura; Suzuka Takahashi; Takeo K Maeda; Kenji Shimizu; Taku Okazaki
Journal:  Nat Immunol       Date:  2018-10-22       Impact factor: 25.606

8.  Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.

Authors:  V Kunzmann; E Bauer; J Feurle; F Weissinger; H P Tony; M Wilhelm
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

Review 9.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

Review 10.  The Natural Cytotoxicity Receptors in Health and Disease.

Authors:  Alexander David Barrow; Claudia Jane Martin; Marco Colonna
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.